当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
13期
22-24
,共3页
养血清脑颗粒%贝那普利片%原发性高血压
養血清腦顆粒%貝那普利片%原髮性高血壓
양혈청뇌과립%패나보리편%원발성고혈압
Yangxueqingnao granula%Benazepril tablets%Essential hypertension
目的观察养血清脑颗粒与盐酸贝那普利片联合使用治疗原发性高血压患者的疗效和安全性.方法将78例原发性高血压患者随机分为2个组,对照组口服盐酸贝那普利片10 mg/次,1次/日、治疗组口服养血清脑颗粒1袋/次,3次/日,盐酸贝那普利片10 mg/次,1次/日.疗程均为4周.观察并记录用药前和用药后血压、心率变化、自觉症状及不良反应.结果治疗后两组患者头痛数字评分呈下降趋势,与对照组治疗后4周评分(4.01±1.10)相比,加用养血清脑颗粒患者治疗后4周头痛数字评分(2.19±1.13),下降有统计学意义,患者头痛程度改善明显(P<0.05).治疗后,治疗组失眠治愈率66.7%,对照组失眠治愈率44.4%,两组疗效相比,差异有统计学意义(P<0.05).两组治疗前后收缩压、舒张压比较差异均有统计学意义(P<0.05).治疗后,治疗组收缩压(126.3±5.4)mmHg、舒张压(78.3±4.6)mmHg,对照组收缩压(136.6±8.8)mmHg、舒张压(88.7±5.9)mmHg,两组血压比较差异有统计学意义(P<0.05).治疗组总有效率97.4%,对照组总有效率84.6%,两组差异有统计学意义(P<0.05),4周末患者收缩压和舒张压均较治疗前显著下降.结论养血清脑颗粒辅助盐酸贝那普利片治疗原发性高血压疗效确切,不良反应少,是治疗原发性高血压的理想选择.
目的觀察養血清腦顆粒與鹽痠貝那普利片聯閤使用治療原髮性高血壓患者的療效和安全性.方法將78例原髮性高血壓患者隨機分為2箇組,對照組口服鹽痠貝那普利片10 mg/次,1次/日、治療組口服養血清腦顆粒1袋/次,3次/日,鹽痠貝那普利片10 mg/次,1次/日.療程均為4週.觀察併記錄用藥前和用藥後血壓、心率變化、自覺癥狀及不良反應.結果治療後兩組患者頭痛數字評分呈下降趨勢,與對照組治療後4週評分(4.01±1.10)相比,加用養血清腦顆粒患者治療後4週頭痛數字評分(2.19±1.13),下降有統計學意義,患者頭痛程度改善明顯(P<0.05).治療後,治療組失眠治愈率66.7%,對照組失眠治愈率44.4%,兩組療效相比,差異有統計學意義(P<0.05).兩組治療前後收縮壓、舒張壓比較差異均有統計學意義(P<0.05).治療後,治療組收縮壓(126.3±5.4)mmHg、舒張壓(78.3±4.6)mmHg,對照組收縮壓(136.6±8.8)mmHg、舒張壓(88.7±5.9)mmHg,兩組血壓比較差異有統計學意義(P<0.05).治療組總有效率97.4%,對照組總有效率84.6%,兩組差異有統計學意義(P<0.05),4週末患者收縮壓和舒張壓均較治療前顯著下降.結論養血清腦顆粒輔助鹽痠貝那普利片治療原髮性高血壓療效確切,不良反應少,是治療原髮性高血壓的理想選擇.
목적관찰양혈청뇌과립여염산패나보리편연합사용치료원발성고혈압환자적료효화안전성.방법장78례원발성고혈압환자수궤분위2개조,대조조구복염산패나보리편10 mg/차,1차/일、치료조구복양혈청뇌과립1대/차,3차/일,염산패나보리편10 mg/차,1차/일.료정균위4주.관찰병기록용약전화용약후혈압、심솔변화、자각증상급불량반응.결과치료후량조환자두통수자평분정하강추세,여대조조치료후4주평분(4.01±1.10)상비,가용양혈청뇌과립환자치료후4주두통수자평분(2.19±1.13),하강유통계학의의,환자두통정도개선명현(P<0.05).치료후,치료조실면치유솔66.7%,대조조실면치유솔44.4%,량조료효상비,차이유통계학의의(P<0.05).량조치료전후수축압、서장압비교차이균유통계학의의(P<0.05).치료후,치료조수축압(126.3±5.4)mmHg、서장압(78.3±4.6)mmHg,대조조수축압(136.6±8.8)mmHg、서장압(88.7±5.9)mmHg,량조혈압비교차이유통계학의의(P<0.05).치료조총유효솔97.4%,대조조총유효솔84.6%,량조차이유통계학의의(P<0.05),4주말환자수축압화서장압균교치료전현저하강.결론양혈청뇌과립보조염산패나보리편치료원발성고혈압료효학절,불량반응소,시치료원발성고혈압적이상선택.
Objective To observe the efficacy and safety about Yangxue Qingnao Granule and benazepril hydrochloride tablets in treatment of patients with essential hypertension. Methods 78 cases with essential hypertension were randomly divided into two groups, the control group (oral hydrochloric benazepril tablets 10 mg/1 times/day), the treatment group (oral Yangxueqingnao granula 1 bag/3 times/day, hydrochloric acid benazepril tablets 10 mg/times/day). Course was 4 weeks. Before and after treatment, blood pressure, heart rate changes, symptoms and adverse reactions were observed and recorded. Results After treatment, headache numeric rating downward trend (rated 4 weeks after treatment 4.01 ± 1.10) compared with the control group, the plus Yangxueqingnao particles patients (4 weeks after treatment 2.19 ± 1.13) headache digital score decreased Statisticssignificance, patients with headache improved significantly (P<0.05). After treatment, the insomnia cure rate of the treatment group 66.7%the insomnia cure rate of the control group was 44.4%, compared to the two groups, the difference was statistically significant (P<0.05). Before and after treatment systolic blood pressure, diastolic blood pressure differences were statistically significant (P<0.05). After treatment, the treatment group, systolic blood pressure (126.3 ± 5.4), diastolic blood pressure (78.3 ± 4.6), systolic blood pressure of the control group (136.6 ± 8.8), diastolic blood pressure (88.7 ± 5.9), two sets of blood pressure difference was statistically significant (P<0.05). The treatment group was 97.4%, 84.6%of the control group, the difference was statistically significant (P<0.05), 4 weekend systolic and diastolic blood pressure than before treatment significantly decreased. Conclusion It is the ideal choice that combine Yangxueqingnao granula and benazepril hydrochloride tablets for the treatment of essential hypertension. Curative effect is exact, adverse, advers reactions were less.